SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease

Press/Media: Press / Media

PeriodNov 17 2015

Media coverage

1

Media coverage

  • TitleSVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date11/17/15
    PersonsFred Poordad, Eric J Lawitz